Key result
Standardized AHF decongestion strategies recommend early combination diuretics targeting spot urinary sodium ≥50 mmol/L.
Why the study?
Despite initial IV loop diuretics, a significant proportion of acute heart failure patients have residual congestion at discharge associated with poor prognosis, necessitating a standardized approach.
A standardized approach to decongestion in acute heart failure, including early combination diuretic therapy and strict monitoring, is essential to achieve euvolemia and improve prognosis.
Answers are grounded in this paper and cite their sources.
Supports urinary sodium-guided decongestion in acute HF; leaves open prospective validation before practice change.
Most episodes of acute heart failure (AHF) are characterized by increasing signs and symptoms of congestion, manifested by edema, pleura effusion and/or ascites. Immediately and repeatedly administered intravenous (IV) loop diuretics currently represent the mainstay of initial therapy aiming to achieve adequate diuresis/natriuresis and euvolemia. Despite these efforts, a significant proportion of patients have residual congestion at discharge, which is associated with a poor prognosis. Therefore, a standardized approach is needed. The door to diuretic time should not exceed 60 min. As a general rule, the starting IV dose is 20-40 mg furosemide equivalents in loop diuretic naïve patients or double the preexisting oral home dose to be administered via IV. Monitoring responses within the following first hours are key issues. (1) After 2 h, spot urinary sodium should be ≥50-70 mmol/L. (2) After 6 h, the urine output should be ≥100-150 mL/hour. If these target measures are not reached, the guidelines currently recommend a doubling of the original dose to a maximum of 400-600 mg furosemide per day and in patients with severely impaired kidney function up to 1000 mg per day. Continuous infusion of loop diuretics offers no benefit over intermittent boluses (DOSE trial). Emerging evidence by recent randomized trials (ADVOR, CLOROTIC) supports the concept of an early combination diuretic therapy, by adding either acetazolamide (500 mg IV once daily) or hydrochlorothiazide. Acetazolamide is particularly useful in the presence of a baseline bicarbonate level of ≥27 mmol/L and remains effective in the presence of preexisting/worsening renal dysfunction but should be used only in the first three days to prevent severe metabolic disturbances. Patients should not leave the hospital when they are still congested and/or before optimized long-term guideline-directed medical therapy has been initiated. Special attention should be paid to AHF patients during the vulnerable post-discharge period, with an early follow-up visit focusing on up-titrate treatments of recommended doses within 2 weeks (STRONG-HF).
No takes yet. Share an insight, caveat, or question.
Bilgeri et al. (2024) conducted a review in Acute heart failure. Standardized decongestion strategy (IV loop diuretics and early combination therapy) was evaluated. A standardized decongestion strategy for acute heart failure recommends early combination diuretic therapy and monitoring to achieve spot urinary sodium ≥50-70 mmol/L after 2 hours.
Synapse has enriched 10 related papers. Consider them for comparative context: